Royalty expected to up $11.25 bid after Elan knockback
This article was originally published in Scrip
Executive Summary
Elan has rejected the $11.25 a share takeover bid from Royalty Pharma. Chairman Robert Ingram said the offer "grossly undervalues Elan's current business platform and our future prospects". It is expected that Royalty will now increase its offer.